Most common adult brain cancer associated with gene deletion
December 23rd, 2010 - 5:47 pm ICT by ANILondon, Dec 23 (ANI): Scientists have discovered an important gene deletion in up to one of every four cases of glioblastoma, the most common adult brain cancer.
This deletion contributes to tumor development, promotes resistance to therapy and considerably worsens a patient’s survival prospects, according to researchers at the Stanford University School of Medicine.
The deletion of the gene, known as NFKBIA, triggers biochemical processes similar to those resulting from a better-known aberration common in glioblastomas: alteration of the epidermal growth factor receptor, or EGFR.
Aberrant EGF receptors continuously send out biochemical signals that direct cells to proliferate, igniting tumor development.
The investigators analyzed several hundred tumor samples collected from glioblastoma patients treated at several institutions between 1989 and 2009, and found NFKBIA deletions in a surprisingly high proportion, 25 percent, of the samples.
They also confirmed earlier findings about EGFR, identifying aberrations in that gene in about one-third of these samples. Interestingly, there were only a handful of instances where both gene aberrations occurred in the same sample.
Thus, the two defects taken together accounted for a majority of all glioblastomas examined.
Moreover, the authors learned, patients with either the NFKBIA or EGFR abnormality had a significantly shorter survival, despite maximal therapy, than the remaining patients whose tumors bore neither genetic defect.
The defects on NFKBIA and EGFR have a similar effect on an important molecule called NF-kappa-B, a “transcription factor” found in all cells, but they do this by different mechanisms.
The finding appeared online Dec. 22 in the New England Journal of Medicine. (ANI)
Ends DW
NNNN
- New treatment strategy effective for certain lung cancers - Mar 11, 2011
- Gold nanoparticles may help detect tumor cells in blood - Feb 12, 2011
- Molecular switch that helps pancreatic cancer beat drugs identified - Jan 29, 2010
- How genetic changes make some brain cancers more aggressive - Oct 02, 2010
- Deadly brain tumour's strength may be a weakness as well - Aug 15, 2010
- Adopting 'synthetic lethality' could boost molecularly targeted cancer therapy - Sep 22, 2010
- Blood test could identify lung cancer patients likely to respond to drug erlotinib - May 01, 2010
- Molecular on-off switches for cancer and autoimmunity defined - Oct 01, 2010
- New hope in the fight against melanoma - Dec 14, 2010
- Chemo-Vandetanib combo effective for lung cancer treatment: Study - Jun 06, 2010
- New potential target for breast cancer therapy identified - Dec 23, 2010
- Evidence of unusual drug-resistant breast tumours found - Oct 09, 2010
- Tiny sacs released by cancer cells may pave way for brain tumour treatment - Nov 17, 2008
- Cancer drugs offer new hope for Crohn's disease and sarcoidosis - Dec 01, 2010
- New therapeutic target for pancreatic cancer found - Apr 19, 2009
Tags: adult brain, biochemical processes, biochemical signals, brain cancer, england journal of medicine, epidermal growth factor, epidermal growth factor receptor, gene aberrations, gene deletion, genetic defect, growth factor receptor, journal of medicine, new england journal, new england journal of medicine, stanford university school, stanford university school of medicine, survival prospects, transcription factor, tumor development, tumor samples